Micromet to Host Conference Call and Webcast to Discuss Blinatumomab Data Presented at EHA on June 8, 2009
June 02 2009 - 7:00AM
PR Newswire (US)
BETHESDA, Md., June 2 /PRNewswire-FirstCall/ -- Micromet, Inc.
(NASDAQ: MITI), a biopharmaceutical company developing novel,
proprietary antibodies for the treatment of cancer, inflammation
and autoimmune diseases, today announced that it will host a
webcast on June 8, 2009 to discuss the blinatumomab data presented
on June 5th and 6th at the 14th Congress of the European Hematology
Association. The webcast will be available on the company's website
at http://www.micromet-inc.com/. Forum: Micromet, Inc. Webcast
Investor Meeting Date: Monday, June 8, 2009 Time: 9:00 am to 11:00
am U.S. Eastern Time Webcast: http://www.micromet-inc.com/ To
participate in this conference call, dial 866-543-6403 (U.S.) or
617-213-8896 (international), passcode: 12594792. The audio webcast
can be accessed at http://www.micromet-inc.com/. A replay of the
call will be available from 1:00 pm Eastern Time on June 8, 2009
(7:00 pm Central European Time) through, June 15, 2009. The replay
number is 888-286-8010 (U.S.) or 617-801-6888 (international),
passcode: 67386852. About Micromet, Inc. Micromet, Inc. is a
biopharmaceutical company developing novel, proprietary antibodies
for the treatment of cancer, inflammation and autoimmune diseases.
Its product development pipeline includes novel antibodies
generated with its proprietary BiTE(R) antibody platform, as well
as conventional monoclonal antibodies. BiTE antibodies represent a
new class of antibodies that activate the T cells of a patient's
immune system to eliminate cancer cells. Four of Micromet's
antibodies are currently in clinical trials. Its BiTE antibody
blinatumomab (MT103) is in a phase 2 clinical trial for the
treatment of patients with acute lymphoblastic leukemia (ALL), and
in a phase 1 clinical trial for the treatment of patients with
non-Hodgkin's lymphoma (NHL). A second BiTE antibody, MT110, is in
a phase 1 clinical trial for the treatment of patients with solid
tumors. MT110 binds to the epithelial cell adhesion molecule, or
EpCAM, which is overexpressed in many solid tumors. Micromet's
human monoclonal antibody adecatumumab (MT201) also binds to EpCAM
and is being developed under a collaboration with Merck Serono.
Adecatumomab is in a phase 2 clinical trial in colorectal carcinoma
patients after complete resection of liver metastases, and a phase
1b clinical trial evaluating adecatumumab in combination with
docetaxel for the treatment of patients with metastatic breast
cancer. Micromet's monoclonal antibody MT293, also known as TRC093,
is licensed to TRACON Pharmaceuticals, Inc., and is in a phase 1
clinical trial for the treatment of patients with cancer. In
addition, Micromet has established a collaboration with Nycomed for
the development and commercialization of MT203, a human antibody
neutralizing the activity of granulocyte/macrophage colony
stimulating factor (GM-CSF), which has potential applications in
the treatment of various inflammatory and autoimmune diseases, such
as rheumatoid arthritis, psoriasis, or multiple sclerosis. Nycomed
has filed a clinical trial application and is expected to commence
a phase 1 clinical trial of MT203 in the first half of 2009.
Micromet's licensee Morphotek, a wholly-owned subsidiary of Eisai,
is also expected to initiate a first phase 1 clinical trial with
Micromet's glycolipid-binding human antibody MT228 for the
treatment of melanoma. Micromet also has entered into an option,
collaboration and license agreement with Bayer Schering Pharma AG
under which Bayer Schering Pharma was granted an exclusive option
to license a specified BiTE antibody against an undisclosed solid
tumor target. Micromet's preclinical product pipeline includes
several novel BiTE antibodies generated with its proprietary BiTE
antibody platform technology. BiTE antibodies targeting CEA, MSCP,
CD33, HER2, EGFR and other targets are in various stages of
preclinical development. Forward-Looking Statements This release
contains certain forward-looking statements that involve risks and
uncertainties that could cause actual results to be materially
different from historical results or from any future results
expressed or implied by such forward-looking statements. These
forward-looking statements include statements regarding the
efficacy, safety and intended utilization of blinatumomab and other
product candidates, the conduct, timing and results of future
clinical trials, and expectations of the future expansion of our
product pipeline and collaborations. You are urged to consider
statements that include the words "ongoing," "may," "will,"
"believes," "potential," "expects," "plans," "anticipates,"
"intends," or the negative of those words or other similar words to
be uncertain and forward-looking. Factors that may cause actual
results to differ materially from any future results expressed or
implied by any forward-looking statements include the risk that
product candidates that appeared promising in early research,
preclinical studies or clinical trials do not demonstrate safety
and/or efficacy in subsequent clinical trials, the risk that
encouraging results from early research, preclinical studies or
clinical trials may not be confirmed upon further analysis of the
detailed results of such research, preclinical study or clinical
trial, the risk that additional information relating to the safety,
efficacy or tolerability of our product candidates may be
discovered upon further analysis of preclinical or clinical trial
data, the risk that we or our collaborators will not obtain
approval to market our product candidates, the risks associated
with reliance on outside financing to meet capital requirements,
and the risks associated with reliance on collaborators, including
MedImmune, Merck Serono, TRACON and Nycomed, for the funding or
conduct of further development and commercialization activities
relating to our product candidates. These factors and others are
more fully discussed in Micromet's Quarterly Report on Form 10-Q
for the fiscal quarter ended March 31, 2009, filed with the SEC on
May 11, 2009, as well as other filings by the company with the SEC.
DATASOURCE: Micromet, Inc. CONTACT: US Media: Andrea tenBroek or
Chris Stamm, +1-781-684-0770, ; European Media: Ludger Wess, +49
(40) 8816 5964, ; US Investors: Susan Noonan, +1-212-966-3650, ;
European Investors: Ines-Regina Buth, +49 (30) 2363 2768, Web Site:
http://www.micromet-inc.com/
Copyright